Literature DB >> 1596011

In vitro conversion of surfactant subtypes is altered in alveolar surfactant isolated from injured lungs.

R Higuchi1, J Lewis, M Ikegami.   

Abstract

Pulmonary alveolar surfactant can be separated into different subtypes on the basis of their buoyant densities. These subtypes have been characterized as ultraheavy and heavy forms, which are surface-active, and light forms, which are less surface active. The ratio of these subtypes was altered in an animal model of acute lung injury that contributed to the physiologic abnormalities. We used an in vitro method of surface-area cycling to compare conversion of heavy subtypes isolated from injured and from normal lungs. Lung injury was induced in adult rabbits with a subcutaneous injection of N-nitroso-N-methylurethane (NNMU). Conversion of NNMU-injured heavy subtypes to light subtypes was significantly greater than normal heavy subtype conversion at each time point studied from 60 to 180 min of cycling (p less than 0.01). Surfactant protein A (SP-A) was added to heavy subtypes, with no effect on conversion when 1.5% SP-A was added, but the addition of 4.5, 10.5, and 22.5% caused complete conversion to ultraheavy forms with no cycling. With subsequent cycling, there was greater conversion from ultraheavy to lighter subtypes for normal surfactant material than for NNMU-injured material (p less than 0.05). We conclude that the altered ratio of surfactant subtypes in the alveolar lavage of injured lungs was due to a greater conversion of these subtypes within the alveolar space. Furthermore, SP-A may play an important role in the metabolism of alveolar surfactant both in normal and in injured lungs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1596011     DOI: 10.1164/ajrccm/145.6.1416

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

Review 1.  Toxic oxidant species and their impact on the pulmonary surfactant system.

Authors:  E Putman; L M van Golde; H P Haagsman
Journal:  Lung       Date:  1997       Impact factor: 2.584

2.  Hyperoxia treatment of TREK-1/TREK-2/TRAAK-deficient mice is associated with a reduction in surfactant proteins.

Authors:  Andreas Schwingshackl; Benjamin Lopez; Bin Teng; Charlean Luellen; Florian Lesage; John Belperio; Riccardo Olcese; Christopher M Waters
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-24       Impact factor: 5.464

3.  Surface properties, morphology and protein composition of pulmonary surfactant subtypes.

Authors:  E Putman; L A Creuwels; L M van Golde; H P Haagsman
Journal:  Biochem J       Date:  1996-12-01       Impact factor: 3.857

4.  Degradation of surfactant-associated protein B (SP-B) during in vitro conversion of large to small surfactant aggregates.

Authors:  R A Veldhuizen; K Inchley; S A Hearn; J F Lewis; F Possmayer
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

5.  Effects of smoke inhalation on alveolar surfactant subtypes in mice.

Authors:  M R Oulton; D T Janigan; J M MacDonald; G T Faulkner; J E Scott
Journal:  Am J Pathol       Date:  1994-10       Impact factor: 4.307

6.  Surfactant-associated protein A is important for maintaining surfactant large-aggregate forms during surface-area cycling.

Authors:  R A Veldhuizen; L J Yao; S A Hearn; F Possmayer; J F Lewis
Journal:  Biochem J       Date:  1996-02-01       Impact factor: 3.857

7.  Surface-area cycling of different surfactant preparations: SP-A and SP-B are essential for large-aggregate integrity.

Authors:  R A Veldhuizen; S A Hearn; J F Lewis; F Possmayer
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

8.  Rapid-Onset Acute Respiratory Distress Syndrome (ARDS) in a Patient Undergoing Metastatic Liver Resection: A Case Report and Review of the Literature.

Authors:  Thorsten Brenner; Johann Motsch; Jens Werner; Lars Grenacher; Eike Martin; Stefan Hofer
Journal:  Anesthesiol Res Pract       Date:  2010-08-15

Review 9.  Clinical review: Exogenous surfactant therapy for acute lung injury/acute respiratory distress syndrome--where do we go from here?

Authors:  Ahilanandan Dushianthan; Rebecca Cusack; Victoria Goss; Anthony D Postle; Mike P W Grocott
Journal:  Crit Care       Date:  2012-11-22       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.